Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 22Recurrence 4Neoplasms 3Plasmablastic Lymphoma 2Leukemia, Myeloid, Acute 2Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Plasma Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 18Cyclophosphamide 17Prednisone 12Doxorubicin 12Vincristine 9Lenalidomide 7ibrutinib 6obinutuzumab 5glofitamab 5Magnetic Resonance Spectroscopy 5polatuzumab vedotin 4fludarabine 4Prednisolone 4Oxaliplatin 4Gemcitabine 4Etoposide 4venetoclax 3pembrolizumab 3fludarabine phosphate 3Whole-Body Irradiation 3Specimen Handling 3R-CHOP protocol 3Cyclosporine 3Biopsy 3zanubrutinib 2prednylidene 2deltacortene 2acalabrutinib 2Mycophenolic Acid 2Ifosfamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × daratumumab × 30 days × Clear all
NCT04824794 2026-05-19

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Genmab

Phase 1/2 Terminated
130 enrolled 40 charts
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡